Real-world (RW) treatment (tx) patterns and outcomes of 3,455 previously untreated mantle cell lymphoma (MCL) patients (pts) in U.S. routine clinical practice.

• DOI: 10.1200/jco.2021.39.15_suppl.7504
• Publication Date: 2021-06-02T14:31:50Z
• Authors: Peter Martin; Michael Wang; Anita Kumar; Keqin Qi; Katherine Daly; Lori Parisi; Angeline Zhu; Gilles A. Salles
• Keywords: Chemoimmunotherapy

7504 Background: MCL is a non-Hodgkin lymphoma with heterogeneous biology and outcomes. We characterized RW tx patterns outcomes of pts to identify factors associated in the US. Methods: This retrospective study included adult diagnosed Jan 2011-Nov 2020 nationwide Flatiron Health EHR-derived deidentified database. Pt characteristics, patterns, time next (rwTTNT, defined as start first-line [1L] subsequent or death) rwOS were evaluated. Results: 3455 included, 85.3% from community oncology setting. In 2946 (85.2%) documented 1L tx, median age was 69.5 y (range 27.7-85.3); 9.5% had blastoid/pleomorphic MCL. 262 (39.6%) 235 (35.6%) 661 available international prognostic index (MIPI) intermediate high risk, respectively. 150/1253 (12.0%) ECOG PS ≥ 2. Chemoimmunotherapy most common including BR 1223 (41.5%), R-CHOP 512 (17.4%) cytarabine (ara-C)-containing 414 (14.1%). 667 received R maintenance (MR). 1036 < 65 y, 243 stem cell transplant (SCT), mainly autologous. 1L-treated pts, follow-up survivors 45.3 mos 0.03-117.2), rwTTNT 24 mos; 36-mo 67%. The Table shows by SCT status. MVA analyses showed 2, LDH/ULN 1, WBC 10 × 9 /L, bulky disease (≥ 5 cm) morphology shorter rwOS; MR independently longer rwOS. who alive did not initiate within 6 (“SCT-eligible”), similar between treated vs without SCT: 65% 59% 86% 85%, Conclusions: this large cohort primarily community-based US practices, for ̃ 2 y. commonly used tx. uncommon even suggesting considerations may influence eligibility availability. Also, clearly As other reports, older high-risk features predictive worse outcome RW, while appeared be better Outcomes across board appear than prospective trials, need focus on developing that can delivered effectively setting.[Table: see text]